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C160 Poster Presentations
±4.19, p<0.0001), synovitis in the suprapatellar recess (8.83
±4.22, p=0.009), and medial parapatellar recesses (9.15 ±4.20,
p=0.042) v.s those patients that did not have.
Stiffness score in WOMAC questionnaire was affected by the
presence of lateral osteophyte (4.02 ±1.95, p=0.001) and the
functional capability was modiﬁed because of the presence of
lateral osteophyte (32.54 ±13.74, p<0.0001), medial osteophyte
(32.17 ±14.4, p<0.0001) and synovitis in the suprapatellar re-
cess (31.72 ±14.26, p=0.001).
Conclusions: -In our population, the most frequent US ﬁnd-
ing was quadricipital enthesophytes. Suprapatellar synovitis was
found in more than half of the patients with symptomatic KOA.
There was a relationship between the number of pathological US
ﬁndings and pain (namely when walking and going up staired),
stiffness and functional ability scores.
Acknowledgements for their collaboration: Ponce A., Díaz-Cor-
dovés G., Fernando JL., Pinto JA., González L., Alcalde M.,
Cobo, T., Vicente E., Rodríguez A., Collado P., Jiménez M.
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Purpose: Studies suggest that some minority groups, especially
African-Americans with osteoarthritis, may be at risk for higher
rates of pain and disability compared to Caucasian Americans.
In addition, African-Americans are less likely to undergo arthro-
plasty compared to Caucasian Americans. Some studies show
that female gender is associated with arthritis impairment. How-
ever, more research needs to be done to evaluate the role of age,
gender, socioeconomic status, and other predictors of arthritis
impairment among minorities and Caucasian Americans.
Methods: The ﬁndings from the population-based 1998 National
Health Interview Survey (N=30,534 adults) were used. Descrip-
tive and correlational procedures evaluated possible Black/White
differences in arthritis impairment related to walking ¼ of a mile
without special equipment.
Results: The null hypothesis was mostly rejected. African-
American women with household incomes less than $20,000
who report that arthritis impairs their daily activities were more
likely than Caucasian-American and African-American men with
arthritis impairment in different income groups to be unable to
walk ¼ of a mile without special equipment. For example, African-
American women with household incomes less than $20,000
who report that arthritis impairs their daily activities were more
likely than Caucasian-American and African-American men with
arthritis impairment in different income groups to be unable to
walk ¼ of a mile without special equipment, after adjusting for
age (r=+0.213, N=340, p<0.000). Among Caucasian-American
women with household incomes at or above $20,000, arthritis
impairment also was positively correlated with being unable to
walk ¼ of a mile without special equipment, after adjusting for
age. However, this partial correlation was very low (r=+0.047,
N=3,150, p<0.008).
Conclusions:These ﬁndings highlight the need to screen for and
aggressively manage arthritis-related pain and disability among
women, especially low-income African-American women.
288
MODELING BLOOD PRESSURE CHANGES ASSOCIATED
WITH LUMIRACOXIB VS IBUPROFEN INTO LONG-TERM
CARDIOVASCULAR AND CEREBROVASCULAR
OUTCOMES AND COSTS
M. Omar1, K. Kahler1, R. Rebuli1, S. Duff2
1Novartis Pharmaceuticals Corporation, E. Hanover, NJ;
2Veritas Health Economics Consulting, Carlsbad, CA
Purpose: Hypertension is a common comorbidity among pa-
tients with osteoarthritis (OA). Traditional NSAIDs used to treat
OA are known to increase blood pressure or to attenuate the
effect of antihypertensive medications. The goal of this analy-
sis was to model the 24 hr systolic ambulatory blood pressure
(SABP) proﬁle into long-term cardiovascular outcomes of a hy-
pothetical cohort of 100,000 controlled hypertensive OA patients
treated with lumiracoxib 100 mg versus ibuprofen 600 mg tid.
Methods: SABP proﬁle was based on results from a 4-week
clinical trial which showed signiﬁcant changes associated with
ibuprofen (+ 2.2 mmHg) vs lumiracoxib (-2.7 mmHg). Framing-
ham risk equations were used in an interactive Excel-based
model to extrapolate these results over a 10-year period and
predict the relationship between SABP changes and the de-
velopment of coronary heart disease (CHD), cerebrovascular
disease (CVD) and congestive heart failure (CHF). Inputs in the
model included common risk factors (age, gender, cardiovas-
cular disease, diabetes, left ventricular hypertrophy, total/HDL
ratio, smoking, and atrial ﬁbrillation), change in 24 hr SABP, and
acute and post-event costs for each of the outcomes of interest
obtained from published sources. Modeled outcomes included
the number of events and the associated costs of managing
these events in ibuprofen and lumiracoxib-treated hypertensive
OA patients.
Results: Table shows outcomes and costs in a cohort of 100,000
patients with the following characteristics: 64 yrs; female, base-
line SABP 127mmHg; total/HDL ratio 4.7; and negative history
of smoking, cardiovascular disease, left ventricular hypertrophy,
atrial ﬁbrillation, or diabetes.
Ibuprofen Lumiracoxib Events Avoided
# MI events 8,761 8,201 560
# Stroke events 5,997 5,244 753
New CHF diagnoses 1,682 1,659 23
Total CV-related deaths 4,759 4,332 427
Costs Avoided
MI Costs $141,374,086 $132,215,429 $9,158,656
Stroke Costs $242,578,501 $212,080,895 $30,497,606
CHF Costs $59,005,390 $58,152,872 $30,497,606
Total Costs 442,957,977 $402,449,196 $40,508,780
Conclusions: Modeling of differential treatment effect on clinical
trial blood pressure data showed that treatment of OA with
lumiracoxib vs a traditional NSAID in a hypertensive population
results in signiﬁcant cardiovascular events avoided and reduced
costs. Future work should address how clinic blood pressure
measures affect results relative to the ambulatory measures
used here.
